PBH— AI Stock Forecast & Price Targets
Published 7/15/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PBH price forecast →
Prestige Consumer Healthcare (PBH) is a defensive OTC healthcare roll-up trading at a depressed 9.3x forward P/E and ~1.18x book after a brutal ~38% 1-year drawdown, driven by an earnings miss, weak FY27 guide, and an investor probe into disclosures. The recent $1.045B Breathe Right acquisition plus LaCorium deal (funded with $400M senior notes) reset the growth story but add leverage into an already-hostile tape; with price at $47.19 versus a $66 consensus target and RSI 45, the risk/reward is asymmetric to the upside, but the Aug 6 earnings print is a binary that gates any near-term thesis.
Do NOT establish a swing position sized for the Aug 6 earnings print (22 days away) — this is a binary event with an active disclosure investigation, and IV is likely elevated per the Zacks options note. For a pre-earnings tactical trade only: a small starter (¼ position) can be justified at $46-47 given proximity to the $45-46 support and the 1d Kronos forecast of $49.95, targeting a bounce to $50-52 with a hard invalidation on a daily close below $45. Flat or hedged into the print is the disciplined stance; the earnings release IS the catalyst and IS the invalidation.
1-6 month thesis: if Aug 6 confirms Breathe Right/LaCorium accretion and management reiterates or firms the FY27 guide, PBH re-rates from 9.3x fwd P/E toward the peer-group 13-15x, implying $55-65 with a base case of $58 (~23% upside). Catalysts: Q1 FY27 print, integration commentary, potential debt paydown cadence, and any resolution of the disclosure inquiry. Change my mind: another revenue miss, a downward FY27 revision, an adverse legal development, or a break of $42.62 on volume — that flips the setup to distributive.
1-3 year terminal thesis: PBH is a durable owner of niche OTC brands (Dramamine, Monistat, Clear Eyes, Summer's Eve, Chloraseptic, Breathe Right) with 55%+ gross margins, high FCF conversion, and a proven M&A playbook. At current 9x FCF and beta 0.34, it's priced as a broken growth stock rather than a defensive cash cow. Multi-year drivers: Breathe Right/LaCorium integration synergies, international OTC expansion, continued tuck-in M&A, and share buybacks funded by $190M+ annual FCF. Biggest structural risk is secular — private-label penetration and Amazon compressing brand equity in undifferentiated OTC categories, plus the goodwill-heavy balance sheet (assets $3.49B vs equity $1.89B) leaves little margin for a large impairment if a franchise (e.g., a wart or lice brand) rolls over.
PBH is a genuinely high-quality specialty consumer-health business masking a soft top line: TTM revenue of $1.089B is down 4.31% Y/Y and Q4 FY26 revenue of $281.6M fell 5.03% Y/Y, yet operating margins remain excellent at 26.8% (gross 55.7%, Q4 gross 51.9%) and profit margin is 17.5%. Cash generation is the crown jewel — FCF of $192.8M against a $2.24B market cap gives a ~8.6% FCF yield and P/FCF of 9.07, well below historical brand-CPG multiples. However, the balance sheet is now the swing factor: total debt of $1.045B versus equity of $1.888B (D/E 0.55) was manageable, but layering on the $1.045B Breathe Right acquisition plus $400M new senior notes for LaCorium meaningfully raises pro-forma leverage into a slowing revenue backdrop. ROE of 10.2% and ROA of 5.4% are unremarkable for a brand company and reflect the goodwill-heavy asset base (total assets $3.49B). Working capital of $310M and current ratio 3.57 provide cushion. Capital allocation history is disciplined M&A, no dividend, and modest buybacks; the fresh acquisitions are on-strategy but need to prove accretive quickly. Trailing EPS $3.91 vs forward $5.07 implies management/street expect deal accretion — this is exactly what the Aug 6 print must validate.
The tape is broken across every timeframe I can see. On the 1D/weekly charts, PBH has collapsed from ~$88 in early January to a fresh cycle low near $45-46, a >45% peak-to-trough decline; the 1-week chart shows a clean lower-high, lower-low downtrend with the current print at $47.19 sitting -19.7% below the 200-SMA and -2.9% below the 50-SMA. YTD -23.5%, Perf Year -38.25%, Perf Half-Year -26.5% — this is capitulation-adjacent, not a healthy consolidation. RSI 45 is neutral (not oversold), and Perf Week -6.4% shows sellers still in control. Support: $45-46 (recent double-bottom on the daily and weekly), then the psychological $42.62 52-week low. Resistance is stacked and heavy: $50 (round number + prior shelf), $52-54 (April breakdown zone visible on 4h), and $60 (200-SMA area and the 1d Kronos forecast). The 1h Kronos forecast projects $49.95 (bullish reversal from $47.99), 4h forecasts $55.99, and 1d $60.15 — but the model's realized 1wk directional accuracy is only 33% vs 83% naive baseline, so the longer-horizon forecast should be heavily discounted. The 1d forecast (74% vs 71% naive) is marginally usable and supports a mean-reversion bounce, not a trend change. Short float 6.88% and short ratio 4.66 add squeeze fuel on any positive catalyst.
Signal: the June 16 8-K confirming a $1.045B Breathe Right acquisition and the July 6 closing of LaCorium Health plus a $400M senior notes offering are the dominant fundamental catalysts — this is the largest acquisition in company history and materially resets the FY27+ revenue and EBITDA trajectory. Ariel Investments publicly reaffirming PBH as a top holding post-deal is a modest institutional endorsement. Offsetting: the June 14 Simply Wall St piece flags the FY26 earnings miss, revenue decline, below-consensus FY27 guide, and a shareholder investigation into whether prior disclosures were misleading — this is the overhang explaining the -38% year. The Zacks options-activity note suggests elevated implied vol into the Aug 6 print, consistent with binary-event pricing. Noise: generic 'top stock' listicles and stocktwits earnings recaps add little. Net: the news flow is bifurcated — bullish structural (deals close, insider/institutional support) versus bearish tactical (miss, weak guide, legal probe).
- Breathe Right brand + ancillary brands acquisition closed June 15 for $1.045B — largest deal in company history, adds a globally recognized nasal-strip franchise to the OTC portfolio
- LaCorium Health acquisition closed July 1, 2026, funded by $400M senior notes — adds international OTC/consumer-health exposure
- Forward EPS of $5.07 vs trailing $3.91 (+30%) implies management expectation of meaningful accretion from the two deals over FY27
- International OTC segment (Fess, Hydralyte in Australia) provides a secular growth lane less exposed to US private-label pressure
- $192.8M annual FCF against $2.24B market cap enables continued deleveraging and/or tuck-in M&A over the next 24 months
- Aug 6, 2026 earnings is a binary event with active shareholder investigation into prior disclosures — headline risk is asymmetric to the downside
- FY26 revenue -4.3% Y/Y and Q4 -5.0% Y/Y suggest organic top line is contracting, meaning M&A must do all the heavy lifting for FY27 growth
- Pro-forma leverage rises materially after $1.045B Breathe Right + $400M senior notes for LaCorium — reduces flexibility if integration slips
- Goodwill-heavy balance sheet ($3.49B assets vs $1.89B equity) exposes book value to impairment risk if any acquired brand underperforms
- Private-label and Amazon-basics competition in commoditized OTC categories is a persistent structural headwind on pricing power
- 1-week Kronos forecast is unreliable (33% directional accuracy vs 83% naive baseline) — do not rely on model-implied $60+ near-term targets
- Technical trend is decisively down: -38% Y/Y, -19.7% below 200-SMA, no confirmed reversal signal yet
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord